【AI详解】The journey of CAR-T therapy in hematological malignancies.

文献信息

一句话小结

CAR-T疗法在血液恶性肿瘤治疗中取得显著成效，许多多线治疗耐药患者实现持久完全缓解，但复发问题仍需关注。本文综述了CAR-T细胞疗法的开发、不同产品的疗效比较及其与其他治疗的结合，为克服耐药性和优化治疗策略提供了重要参考。

在麦伴科研 (maltsci.com) 搜索更多文献

CAR-T细胞疗法 · 组合疗法 · 药物产品 · 血液系统恶性肿瘤 · 靶向疗法

摘要

嵌合抗原受体T细胞（CAR-T）疗法彻底改变了血液恶性肿瘤的治疗模式，许多多线治疗耐药的患者实现了持久的完全缓解（CR）和相对较高的客观反应率（ORR）。截至目前，已经开发出多种CAR-T产品，如Kymriah、Yescarta和Tecartus，并取得了前所未有的效果。然而，一些患者在治疗后可能会复发，这促使研究者们深入探讨克服耐药性和复发机制的新策略。显著的技术进展，如纳米抗体和CRISPR-Cas9，亦在不断推进，以确保CAR-T细胞疗法充分发挥其医疗潜力。在本综述中，我们概述了CAR-T细胞疗法开发和生产过程的基本原则，总结了不同产品在疗效上的相似性和差异及其对应的临床结果，并讨论了CAR-T免疫疗法与其他药物治疗的临床效果结合的情况。

英文摘要

Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment paradigms for hematological malignancies, with multi-line therapy-refractory patients achieving durable complete remissions (CR) and relatively high objective response rate (ORR). So far, many CAR-T products, such as Kymriah, Yescarta and Tecartus, have been developed and got the unprecedented results. However, some patients may relapse afterwards, driving intense investigations into promoting the development of novel strategies to overcome resistance and mechanisms of relapse. Notable technical progress, such as nanobodies and CRISPR-Case9, has also taken place to ensure CAR-T cell therapy fully satisfies its medical potential. In this review, we outline the basic principles for the development and manufacturing processes of CAR-T cell therapy, summarize the similarities and differences in efficacy of different products as well as their corresponding clinical results, and discuss CAR-T immunotherapy combined with other clinical effects of drug therapy.

麦伴智能科研服务

主要研究问题

1. CAR-T疗法在不同类型的血液恶性肿瘤中的疗效差异是什么？
2. 目前有哪些新兴的策略可以有效应对CAR-T疗法后的复发问题？
3. CRISPR-Cas9技术在CAR-T细胞治疗中的应用前景如何？
4. 不同CAR-T产品的生产过程和临床应用中存在哪些关键的技术挑战？
5. CAR-T免疫治疗与其他药物疗法的联合使用效果如何评估？

核心洞察

研究主题和范围

本综述文章探讨了嵌合抗原受体T细胞（CAR-T）疗法在血液恶性肿瘤治疗中的发展历程及其最新进展。作者回顾了CAR-T疗法的基本原理、制造过程、不同产品的疗效与临床结果，并讨论了与其他治疗的联合应用。

主要发现和观点

• CAR-T疗法的革命性：CAR-T细胞疗法已成为治疗血液恶性肿瘤的关键方法，特别是在治疗难治性和复发性癌症患者中，取得了显著的临床效果。
• 技术进步：CAR-T疗法经历了五代的发展，最新的技术进展包括使用纳米抗体和CRISPR技术，以增强CAR-T细胞的疗效和安全性。
• 不良反应：尽管CAR-T疗法有效，但也伴随有严重的副作用，如细胞因子释放综合症（CRS）和免疫效应细胞相关神经毒性综合症（ICANS），需要采取措施降低其发生率。

研究进展

• 产品比较：不同CAR-T产品（如Kymriah、Yescarta、Tecartus等）在疗效和安全性上存在差异。文章详细总结了各个产品在临床试验中的有效性和不良事件发生率。
• 联合疗法的潜力：CAR-T疗法与其他免疫检查点抑制剂（如PD-1/PD-L1抑制剂）及小分子抑制剂（如BTK抑制剂）联合使用显示出更好的临床效果，尤其在抵抗机制方面表现出色。

争议与不足

• 耐药机制：一些患者在接受CAR-T疗法后出现复发，研究者们正在深入探讨肿瘤耐药的机制，如肿瘤抗原丢失和肿瘤微环境的免疫抑制。
• 制造复杂性：CAR-T细胞的制造过程复杂且时间长，限制了其广泛应用。需要进一步研究以优化生产流程。

未来研究方向

• 新技术的应用：未来的研究应集中在新型CAR构建的开发、基因编辑技术的应用（如CRISPR/Cas9）以及改进制造工艺（如MASTER技术）上，以提高CAR-T疗法的安全性和有效性。
• 长期疗效和安全性：需要进行更多的临床试验，以验证新策略的有效性，并监测长期疗效和潜在的副作用。

本综述为CAR-T细胞疗法的现状和未来发展提供了全面的视角，强调了其在血液恶性肿瘤治疗中的重要性及面临的挑战。

参考文献

1. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. - Agrima Mian;Brian T Hill - Expert opinion on biological therapy (2021)
2. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. - Donglei Han;Zenghui Xu;Yuan Zhuang;Zhenlong Ye;Qijun Qian - Journal of Cancer (2021)
3. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. - Christopher A Klebanoff;Joseph G Crompton;Anthony J Leonardi;Tori N Yamamoto;Smita S Chandran;Robert L Eil;Madhusudhanan Sukumar;Suman K Vodnala;Jinhui Hu;Yun Ji;David Clever;Mary A Black;Devikala Gurusamy;Michael J Kruhlak;Ping Jin;David F Stroncek;Luca Gattinoni;Steven A Feldman;Nicholas P Restifo - JCI insight (2017)
4. CRISPR-engineered T cells in patients with refractory cancer. - Edward A Stadtmauer;Joseph A Fraietta;Megan M Davis;Adam D Cohen;Kristy L Weber;Eric Lancaster;Patricia A Mangan;Irina Kulikovskaya;Minnal Gupta;Fang Chen;Lifeng Tian;Vanessa E Gonzalez;Jun Xu;In-Young Jung;J Joseph Melenhorst;Gabriela Plesa;Joanne Shea;Tina Matlawski;Amanda Cervini;Avery L Gaymon;Stephanie Desjardins;Anne Lamontagne;January Salas-Mckee;Andrew Fesnak;Donald L Siegel;Bruce L Levine;Julie K Jadlowsky;Regina M Young;Anne Chew;Wei-Ting Hwang;Elizabeth O Hexner;Beatriz M Carreno;Christopher L Nobles;Frederic D Bushman;Kevin R Parker;Yanyan Qi;Ansuman T Satpathy;Howard Y Chang;Yangbing Zhao;Simon F Lacey;Carl H June - Science (New York, N.Y.) (2020)
5. CD19 CAR T Cells. - Michel Sadelain - Cell (2017)
6. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. - Marco Ruella;Jun Xu;David M Barrett;Joseph A Fraietta;Tyler J Reich;David E Ambrose;Michael Klichinsky;Olga Shestova;Prachi R Patel;Irina Kulikovskaya;Farzana Nazimuddin;Vijay G Bhoj;Elena J Orlando;Terry J Fry;Hans Bitter;Shannon L Maude;Bruce L Levine;Christopher L Nobles;Frederic D Bushman;Regina M Young;John Scholler;Saar I Gill;Carl H June;Stephan A Grupp;Simon F Lacey;J Joseph Melenhorst - Nature medicine (2018)
7. B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation. - Mark D Singh;Minjian Ni;Jenna M Sullivan;Jessica A Hamerman;Daniel J Campbell - The Journal of experimental medicine (2018)
8. Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. - Ken Ogasawara;Michael Dodds;Timothy Mack;James Lymp;Justine Dell’Aringa;Jeff Smith - Clinical pharmacokinetics (2021)
9. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. - Shannon L Maude;Theodore W Laetsch;Jochen Buechner;Susana Rives;Michael Boyer;Henrique Bittencourt;Peter Bader;Michael R Verneris;Heather E Stefanski;Gary D Myers;Muna Qayed;Barbara De Moerloose;Hidefumi Hiramatsu;Krysta Schlis;Kara L Davis;Paul L Martin;Eneida R Nemecek;Gregory A Yanik;Christina Peters;Andre Baruchel;Nicolas Boissel;Francoise Mechinaud;Adriana Balduzzi;Joerg Krueger;Carl H June;Bruce L Levine;Patricia Wood;Tetiana Taran;Mimi Leung;Karen T Mueller;Yiyun Zhang;Kapildeb Sen;David Lebwohl;Michael A Pulsipher;Stephan A Grupp - The New England journal of medicine (2018)
10. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. - Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak;Mounzer Agha;Adam D Cohen;A Keith Stewart;Parameswaran Hari;Myo Htut;Alexander Lesokhin;Abhinav Deol;Nikhil C Munshi;Elizabeth O’Donnell;David Avigan;Indrajeet Singh;Enrique Zudaire;Tzu-Min Yeh;Alicia J Allred;Yunsi Olyslager;Arnob Banerjee;Carolyn C Jackson;Jenna D Goldberg;Jordan M Schecter;William Deraedt;Sen Hong Zhuang;Jeffrey Infante;Dong Geng;Xiaoling Wu;Marlene J Carrasco-Alfonso;Muhammad Akram;Farah Hossain;Syed Rizvi;Frank Fan;Yi Lin;Thomas Martin;Sundar Jagannath - Lancet (London, England) (2021)

引用本文的文献

1. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. - Qiuqiang Chen;Lingeng Lu;Wenxue Ma - Cancers (2022)
2. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. - Stephen Jolles;Sergio Giralt;Tessa Kerre;Hillard M Lazarus;S Shahzad Mustafa;Roberto Ria;Donald C Vinh - Frontiers in oncology (2023)
3. Emerging roles of the gut microbiota in cancer immunotherapy. - Zhuangzhuang Shi;Hongwen Li;Wenting Song;Zhiyuan Zhou;Zhaoming Li;Mingzhi Zhang - Frontiers in immunology (2023)
4. Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. - Shivani Thoidingjam;Sushmitha Sriramulu;Svend Freytag;Stephen L Brown;Jae Ho Kim;Indrin J Chetty;Farzan Siddiqui;Benjamin Movsas;Shyam Nyati - Translational medicine communications (2023)
5. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. - Shengkang Huang;Xinyu Wang;Yu Wang;Yajing Wang;Chenglong Fang;Yazhuo Wang;Sifei Chen;Runkai Chen;Tao Lei;Yuchen Zhang;Xinjie Xu;Yuhua Li - Molecular cancer (2023)
6. Thermoresponsive Polypeptide Fused L-Asparaginase with Mitigated Immunogenicity and Enhanced Efficacy in Treating Hematologic Malignancies. - Sanke Zhang;Yuanzi Sun;Longshuai Zhang;Fan Zhang;Weiping Gao - Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
7. Regeneration of T cells from human-induced pluripotent stem cells for CAR-T cell medicated immunotherapy. - Yanyan Chen;Pufeng Huang;Mengda Niu;Chuanhuizi Tian;Tingting Zhang;Zhiping Peng - Frontiers in bioengineering and biotechnology (2023)
8. Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics. - Jiali Cheng;Yuyan Zhao;Hui Hu;Ling Tang;Yuhao Zeng;Xinyue Deng;Shengnan Ding;An-Yuan Guo;Qing Li;Xiaojian Zhu - Cancer immunology, immunotherapy : CII (2023)
9. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. - Chunmei Hu;Min Liu;Yutao Li;Yi Zhao;Amit Sharma;Haotian Liu;Ingo G H Schmidt-Wolf - Frontiers in immunology (2023)
10. PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer. - Behnia Akbari;Tahereh Soltantoyeh;Zahra Shahosseini;Farhad Jadidi-Niaragh;Jamshid Hadjati;Christine E Brown;Hamid Reza Mirzaei - Frontiers in immunology (2023)

… (91 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研